• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal Phase III trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.